From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention

被引:17
|
作者
Motta, Benedetta Maria [1 ]
Masarone, Mario [1 ]
Torre, Pietro [1 ]
Persico, Marcello [1 ]
机构
[1] Univ Salerno, Scuola Med Salernitana, Dept Med Surg & Dent, I-84081 Baronissi, Italy
关键词
NAFLD; NASH; HCC; SNP; FATTY LIVER-DISEASE; VITAMIN-E; CARDIOVASCULAR-DISEASE; GLOBAL EPIDEMIOLOGY; PORTAL-HYPERTENSION; DIABETES-MELLITUS; NATURAL-HISTORY; ALCOHOLIC LIVER; CANCER; CIRRHOSIS;
D O I
10.3390/cancers15225458
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Non-alcoholic fatty liver disease affects up to a quarter of the adult population in many developed and developing countries. This disease has become the fastest-growing cause of hepatocellular carcinoma (HCC) in industrialized countries. The annual incidence of hepatocarcinoma varies between patients with cirrhosis and noncirrhotic patients. In this review, HCC associated with non-alcoholic fatty liver disease will be described, considering its epidemiology, risk factors, and management, including preventive strategies and therapeutic approaches.Abstract Non-alcoholic fatty liver disease (NAFLD) affects up to a quarter of the adult population in many developed and developing countries. This spectrum of liver disease ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. The incidence of NASH is projected to increase by up to 56% over the next 10 years. There is growing epidemiological evidence that NAFLD has become the fastest-growing cause of hepatocellular carcinoma (HCC) in industrialized countries. The annual incidence of HCC varies between patients with NASH cirrhosis and patients with noncirrhotic NAFLD. In this review, NAFLD/NASH-associated HCC will be described, including its epidemiology, risk factors promoting hepatocarcinogenesis, and management of HCC in patients with obesity and associated metabolic comorbidities, including preventive strategies and therapeutic approaches to address this growing problem.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] Outcomes of liver transplantation in non-alcoholic steatohepatitis (NASH) versus non-NASH associated hepatocellular carcinoma
    Rajendran, Luckshi
    Perez, Carla F. Murillo
    Ivanics, Tommy
    Claasen, Marco P. A. W.
    Hansen, Bettina E.
    Wallace, David
    Yoon, Peter D.
    Sapisochin, Gonzalo
    HPB, 2023, 25 (05) : 556 - 567
  • [22] Hepatocellular carcinoma arising in non-alcoholic steatohepatitis
    Zen, Y
    Katayanagi, K
    Tsuneyama, K
    Harada, K
    Araki, I
    Nakanuma, Y
    PATHOLOGY INTERNATIONAL, 2001, 51 (02) : 127 - 131
  • [23] Effects of Telmisartan on a Murine Model of Non-Alcoholic Steatohepatitis (NASH) and NASH-Related Hepatocellular Carcinoma
    Shibazaki, Yuichiro
    Fujii, Masato
    Wakamatsu, Kyoko
    Hashiguchi, Taishi
    Honma, Taihei
    Furuuchi, Miho
    Sakurai, Maki
    Nishimura, Nobuyo
    Yoneyama, Hiroyuki
    GASTROENTEROLOGY, 2012, 142 (05) : S543 - S543
  • [24] Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms
    Lequoy, Marie
    Gigante, Elia
    Couty, Jean-Pierre
    Desbois-Mouthon, Christele
    HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION, 2020, 41 (01)
  • [25] Expression of Miscellaneous Genes Upregulated in Hepatocellular Carcinoma in Patients with Alcoholic (ASH) and Non-alcoholic Steatohepatitis (NASH)
    Lu, Jiajie
    Nguyen, Luan
    Samadzadeh, Sara
    Masouminia, Maryam
    Mendoza, Alejandro
    Tillman, Brittany
    Morgan, Timothy
    French, Barbara
    French, Samuel
    FASEB JOURNAL, 2018, 32 (01):
  • [26] NON-ALCOHOLIC STEATOHEPATITIS TRANSPLANT RECIPIENTS ARE AT HIGH RISK FOR HEPATOCELLULAR CARCINOMA
    Hernandez-Alejandro, Roberto
    Marotta, Paul J.
    Wall, William J.
    Quan, Douglas
    LIVER TRANSPLANTATION, 2008, 14 (07) : S205 - S205
  • [27] Non-alcoholic fatty liver disease (NAFLD) progression to non-alcoholic steatohepatitis (NASH) and NASH-related hepatocellular carcinoma (HCC) evolves following a differential activation of endoplasmic reticulum stress responses
    Finnemore, Alexander
    Maria Herranz, Jose
    Barace, Sergio
    Infante, Stefany
    Avila, Matias A.
    Garcia-Porrero, Guillermo
    Arcelus, Sara
    Santamaria, Eva
    Argemi, Josepmaria
    JOURNAL OF HEPATOLOGY, 2022, 77 : S697 - S697
  • [28] Oral administration of lactic acid bacteria prevents inflammation and steatosis in a murine model of non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC)
    Tsuji, N.
    Suabjakyong, P.
    Watanabe, Y.
    Kamiya, T.
    Kimoto-Nira, H.
    Kanto, T.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 348 - 348
  • [29] Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma
    Shuichiro Shiina
    Hitoshi Maruyama
    Maki Tobari
    Tatsuya Yamashita
    Hepatology International, 2023, 17 : 827 - 829
  • [30] Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma
    Shiina, Shuichiro
    Maruyama, Hitoshi
    Tobari, Maki
    Yamashita, Tatsuya
    HEPATOLOGY INTERNATIONAL, 2023, 17 (04) : 827 - 829